Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact

Pérez-Castro, Sonia; Lorenzo-Mahía, Y.; Fernández, Amparo Iñarrea; Lamas-González, María José; Sarán-Díez, María Teresa; Rubio-Alarcón, Joaquín; Reboredo-Reboredo, María Consuelo; Mosteiro-Lobato, Sonia; López-Miragaya, Isabel; Torres-Piñón, Julio; Melón, Santiago

doi:10.1016/j.eimc.2013.09.011

Cited by 7 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main consequence of HR-HPV infection is cervical cancer, which is one of the leading causes of cancer-related mortality in women [ 3 ]. This relationship accounts for 99.7% of cervical cancer worldwide and 96.8% in our community, as described in detail previously [ 4 ]. Moreover, previous studies suggested that cancers of penis and cervix may share the same aetiological factors [ 5 ].…”

Section: Introductionsupporting

confidence: 64%

“…The following variables were studied: age, nationality, HR-HPV infection and specific HPV genotype, age at first sexual intercourse (FSI), number of sexual partners (SP) in the year preceding the study, number of sexual partners up to the date of the study, smoking in the last year, circumcision, regular condom use in the last year, and presentation of genital warts. An extended questionnaire ( S1 Appendix ) was validated in a previous study by our team [ 4 ] with the assistance of a research statistician, and only those questions considered the most interesting for this study and population were selected.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population

López-Diez

Pérez²,

Carballo

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundHigh risk human papillomavirus (HR-HPV) infection in males is a health issue with implications for HPV-related lesions in their partners. The identification of risk factors for male infection may improve our understanding of HR-HPV transmission and prevention. The aim of this study was to evaluate the relationships between lifestyle, genital warts and HR-HPV infection. The study was focused on men with an increased risk of HR-HPV infection: male sexual partners of women diagnosed with high-grade squamous intraepithelial cervical lesions.MethodsMen were enrolled and prospectively recruited within the first six months after diagnosis of cervical lesions in their female partners (n = 175, 2013–2016). Epidemiological and sexual behaviour data were obtained. The presence of genital warts was established by visual inspection. Detection and genotyping of HR-HPV infection in genital samples were performed with a Linear Array HPV Genotyping Test. All HR-HPV positive men were offered a follow-up exam at 12 months. SPSS version 19 was used for statistical analysis.Results and discussionThe prevalence of HR-HPV infection in men was 45.1% (79/175). Genital warts were observed in 10.3% (18/175) of the subjects. Detection of genital warts (OR 3.5, p = 0.015), smoking habits (OR 2.3, p = 0.006) and sexual debut before 16 years old (OR 2, p = 0.035) were associated with an increased risk for HR-HPV infection (univariate analysis). This association was also observed for genital warts and smoking status in a multivariate analysis. The same genotype was found after one year in 71.4% (20/28) of subjects.ConclusionsThe presence of genital warts and smoking habits seem to be associated with a higher risk of HR-HPV infection in males. Earlier sexual debut may increase this risk. Extensive knowledge of the natural history of HR-HPV infection in males is an absolute requirement for the design and implementation of prevention strategies for the general population as well as for specific populations such as couples after treatment for high-grade cervical lesions.

show abstract

Section: Introductionsupporting

confidence: 64%

Section: Methodsmentioning

confidence: 99%

Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population

López-Diez

Pérez²,

Carballo

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The lower pooled prevalence in earlier publications might therefore be due to the detection method used and potentially not to a change in HPV prevalence over time. Age-specific prevalence curves among men are flatter [19,28,29] in contrast to the pattern observed in women [30]. The prevalence of genital infection in men does not differ significantly among age groups as it does in females [30].…”

Section: Hr-hpv Prevalence In Heterosexual Men Populationsmentioning

confidence: 73%

“…Age-specific prevalence curves among men are flatter [19,28,29] in contrast to the pattern observed in women [30]. The prevalence of genital infection in men does not differ significantly among age groups as it does in females [30]. In general population, HPV infection has a consistently higher prevalence within the penile epithelium of asymptomatic men than within the cervix of women with normal cytological testing [29].…”

Section: Hr-hpv Prevalence In Heterosexual Men Populationsmentioning

confidence: 84%

Diagnosis and Prevalence of High-Risk Human Papillomavirus Infection in Heterosexual Men

López-Diez¹,

Pérez²,

Iñarrea³

2016

Human Papillomavirus - Research in a Global Perspective

View full text Add to dashboard Cite

A better understanding of human papillomavirus (HPV) infection in men is an essential component of prevention programs aimed to reduce cervical cancer and other HPVrelated diseases. A screening test capable of detecting asymptomatic/subclinical genital HPV infection in men at a reasonable price and causing minimal discomfort to the patient would be very valuable. The following chapter focuses on acetowhite test usefulness in the detection of asymptomatic/subclinical genital high-risk (HR) HPV infection in highrisk men populations, HR-HPV prevalence in sexually active healthy male partners of women diagnosed of high-grade cervical intraepithelial neoplasia and genotypespecific concordance between partners, addressing the preventive strategies that would reduce HPV infection in men. We present data from 125 men, sexual partners of women with preneoplastic cervical lesions. Prevalence of HR-HPV infection in male was high (50, 24% HPV16) and genotype concordance within the 60 infected couples was remarkable (62% shared at least one genotype). Acetowhite (AW) test was positive in 27% patients, showing low sensitivity for the identification of HR-HPV infection but allowed the diagnosis of subclinical HPV-related lesions in more than 10%. Current smoking and genital warts were associated with an increased risk of HR-HPV infection in men (OR: 2.4 and 5.6, respectively).

show abstract

“…Some initial studies have evidence to suggest that rates of cervical pre‐cancers are also declining. Using linear array HPV genotyping test, it was shown that vaccination against HPV could reduce the cumulative incidence of cervical intraepithelial neoplasia grade 2 or higher by 50.6% via direct protection against high‐risk HPV and 62.7% via cross‐protection against other subtypes . In a large study of 14 085 unvaccinated and 24 871 vaccinated women in Australia, it was found that histological and cytological high‐grade abnormalities were significantly more frequent in unvaccinated compared with vaccinated women within 5 years of vaccine implementation .…”

Section: Prophylactic Vaccinesmentioning

confidence: 99%

Recent progress in vaccination against human papillomavirus‐mediated cervical cancer

McKee

Bergot

Leggatt

2015

Reviews in Medical Virology

View full text Add to dashboard Cite

It has been more than 7 years since the commercial introduction of highly successful vaccines protecting against highrisk human papillomavirus (HPV) subtypes and the development of cervical cancer. From an immune standpoint, the dependence of cervical cancer on viral infection has meant that HPV proteins can be targeted as strong tumour antigens leading to clearance of the infection and the subsequent protection from cancer. Commercially available vaccines consisting of the L1 capsid protein assembled as virus-like particles (VLPs) induce neutralising antibodies that deny access of the virus to cervical epithelial cells. While greater than 90% efficacy has been demonstrated at the completion of large phase III trials in young women, vaccine developers are now addressing broader issues such as efficacy in boys, longevity of the protection and inducing cross-reactive antibody for oncogenic, non-vaccine HPV strains. For women with existing HPV infection, the prophylactic vaccines provide little protection, and consequently, the need for therapeutic vaccines will continue into the future. Therapeutic vaccines targeting HPVE6 and E7 proteins are actively being pursued with new adjuvants and delivery vectors, combined with an improved knowledge of the tumour microenvironment, showing great promise. This review will focus on recent progress in prophylactic and therapeutic vaccine development and implementation since the publication of end of study data from phase III clinical trials between 2010 and 2012. Copyright © 2015 John Wiley & Sons, Ltd. INTRODUCTIONTargeting cancers for immunotherapy is often complicated by a lack of immunogenic tumour peptides. Mutated or overexpressed self-antigens are frequently the targets and invoke a generally low affinity/avidity T and B cell response. In contrast, the tight association between infection with HPV and cervical cancer means that foreign viral proteins encoded by HPV can provide the basis of either prophylactic or therapeutic cancer vaccines [1,2]. The natural course of anogenital HPV infection results in overwhelming clearance of the virus in 98% of individuals with an immune component suggested by the increased risk of HPV-associated cancers in immune-compromised organ transplant recipients [3,4]. However, HPV genotype-specific antibodies against the viral capsid proteins (L1 and L2) are produced at only low levels in about half the patients, can take close to a year to develop after natural infection and associate with higher viral loads in the cervix [5]. Thus, natural antibody may reflect the non-lytic, localised, intracellular nature of the infection leading to poor immunogenicity for immunoglobulin production and a greater emphasis on T-cell immunity for viral clearance. In contrast, prior immunization with HPV capsid proteins in animal studies induces high titres of antibody that are protective against challenge infection. Early studies in dogs demonstrated that prior immunization with L1 capsid protein could protect beagles from mucosal challenge with canine oral ...

show abstract

Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact

Cited by 7 publications

References 29 publications

Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population

Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population

Diagnosis and Prevalence of High-Risk Human Papillomavirus Infection in Heterosexual Men

Recent progress in vaccination against human papillomavirus‐mediated cervical cancer

Contact Info

Product

Resources

About